AP2005003411A0 - A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists. - Google Patents

A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists.

Info

Publication number
AP2005003411A0
AP2005003411A0 AP2005003411A AP2005003411A AP2005003411A0 AP 2005003411 A0 AP2005003411 A0 AP 2005003411A0 AP 2005003411 A AP2005003411 A AP 2005003411A AP 2005003411 A AP2005003411 A AP 2005003411A AP 2005003411 A0 AP2005003411 A0 AP 2005003411A0
Authority
AP
ARIPO
Prior art keywords
humans
prevention
growth factor
hepatocyte growth
malaria infection
Prior art date
Application number
AP2005003411A
Other languages
English (en)
Inventor
Maria M Mota
Ana Rodriguez
Silvia Giordano
Original Assignee
Inst Gulbenkian De Ciencia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Gulbenkian De Ciencia filed Critical Inst Gulbenkian De Ciencia
Publication of AP2005003411A0 publication Critical patent/AP2005003411A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
AP2005003411A 2003-03-12 2004-03-11 A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists. AP2005003411A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45348303P 2003-03-12 2003-03-12
PCT/US2004/007516 WO2004080420A2 (en) 2003-03-12 2004-03-11 A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists

Publications (1)

Publication Number Publication Date
AP2005003411A0 true AP2005003411A0 (en) 2005-12-31

Family

ID=32990777

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003411A AP2005003411A0 (en) 2003-03-12 2004-03-11 A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists.

Country Status (8)

Country Link
US (1) US7670631B2 (pt)
EP (1) EP1601378A2 (pt)
JP (1) JP2007525428A (pt)
CN (1) CN1809382A (pt)
AP (1) AP2005003411A0 (pt)
BR (1) BRPI0408268A (pt)
WO (1) WO2004080420A2 (pt)
ZA (1) ZA200508178B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7968605B2 (en) 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
AU2003208525B9 (en) 2002-02-04 2009-08-27 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Amend the invention title to read Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
GB2395432B (en) 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
CN1255106C (zh) * 2003-09-26 2006-05-10 李国桥 复方青蒿素
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US7566465B2 (en) * 2006-12-21 2009-07-28 The United States Of America As Represented By The Secretary Of The Army Artemisinins in the clinical and veterinary management of kinetoplastid infections
WO2008147826A1 (en) * 2007-05-22 2008-12-04 Seattle Biomedical Research Institute Malaria liver stage drugs
ES2537201T3 (es) 2008-02-05 2015-06-03 Aptahem Ab Selección de aptámeros de ARN como agentes antipalúdicos
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
CA2772085A1 (en) * 2009-08-27 2011-03-03 The U.S.A., As Represented By The Secretary, Dept. Of Health And Human S Ervices Compounds that treat malaria and prevent malaria transmission
FR2952823B1 (fr) * 2009-10-30 2012-04-20 Sanofi Aventis Utilisation de la ferroquine dans le traitement ou la prevention du paludisme
EP2512504A4 (en) * 2009-12-15 2013-06-19 Dec Int Nz Ltd COMPOSITION AND THERAPEUTIC METHOD
MX2012008961A (es) * 2010-02-03 2013-04-29 Meh Associates Inc Fluorometanos multiples sustituidos como isosteros selectivos y bioactivos.
EP2404601A1 (en) * 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
WO2012135064A2 (en) * 2011-03-25 2012-10-04 The Regents Of The University Of California Attenuated strains of plasmodium
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US9918989B2 (en) 2013-07-12 2018-03-20 The Regents Of The University Of California Combination therapies for malaria
WO2015178940A1 (en) * 2014-05-20 2015-11-26 American University Of Cairo (Auc) Ligands that target plasmodium sporozoite binding sites on cd81 and therapeutic methods using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) * 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US6887499B2 (en) * 2000-05-22 2005-05-03 Enitan A. Bababunmi Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease

Also Published As

Publication number Publication date
JP2007525428A (ja) 2007-09-06
US20040185050A1 (en) 2004-09-23
EP1601378A2 (en) 2005-12-07
US7670631B2 (en) 2010-03-02
ZA200508178B (en) 2007-04-25
BRPI0408268A (pt) 2006-03-07
WO2004080420A3 (en) 2004-11-25
CN1809382A (zh) 2006-07-26
WO2004080420A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
ZA200508178B (en) A method for the prevention of malaria infection of humans by hepatocyte growth factor antagonists
PL1740156T3 (pl) Sposób wytwarzania zabezpieczonej przed nadużyciem, stałej postaci aplikacyjnej
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
IL170115A (en) Feedback loop for spam prevention
PL376792A1 (pl) Sposoby szczepienia przeciwko malarii
DK2135957T3 (da) Fremgangsmåde til fremstilling af glucaner
IL180893A0 (en) Method for the preparation of a d-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative
NO20052158L (no) Fremgangsmate for fremstilling av en benzimidazolforbindelse.
ITRM20040015A1 (it) Procedimento per la composizione di un rivestimento nanocomposito.
PT1753393T (pt) Procedimento de inoformulação de uma base galénica biocompatível
HK1072964A1 (en) Method for the assembly of a stay
DE60233478D1 (de) Gruppe iii nitrid-basiertes lichtemittierendes halbleiterbauelement und verfahren zu dessen herstellung
AU2003299284A8 (en) Method for the production of a semiconductor component
NO20041150L (no) Fremgangsmate for a danne en sammenfoyning.
HK1075936A1 (en) Vaccine for the prevention of malaria
FI20021968A0 (fi) Menetelmä hiivojen kasvun estämiseksi
NL1021490A1 (nl) Werkwijze voor de bereiding van een fluorpolymeer.
TWI315290B (en) Method for the operation of a lift installation
EP1556400A4 (en) PROCESS FOR THE PREPARATION OF 2-HALOGEN-2-DESOXYADENOSINE COMPOUNDS FROM 2-DESOXYGUANOSINE
ITMI20030479A1 (it) Procedimento per la preparazione di un ciano-isobenzofurano.
ITBO20020602A1 (it) Apparecchiatura per la realizzazione di decori artistici,
ZA200302618B (en) Process for the preparation of cyclic diketones.
FI20031087A0 (fi) Menetelmä nosturin ohjaamiseksi
NO20042377D0 (no) Fremgangsmate for frigivelse av laminater
AP2003002864A0 (en) Method for making building elements.